Home Emerging Therapy Novel Peanut Allergy Vaccine Begins Phase I Clinical Trials

Novel Peanut Allergy Vaccine Begins Phase I Clinical Trials


A novel vaccine intended to reprogram the immune system to tolerate peanut has begun Phase I clinical trials in Australia on individuals 18-65 years of age. The vaccine candidate, dubbed PVX108, is the result of over fifteen years of research and development conducted by Alfred Health and Monash University.

The vaccine employs peptides – components of proteins – that are selected from specific parts of the peanut protein that do not cause life-threatening anaphylactic reactions. As a result, the vaccine itself is expected to be well-tolerated.

Click to visit sponsor

Pascal Hickey, CEO of Aravax, the company formed to commercialize PVX108, said:

Dr Pascal Hickey
Dr Pascal Hickey

We want to help people around the world who suffer from peanut allergy to live stress-free lives without constantly fearing a major health event from accidental consumption. Our technology aims to alleviate that stress by reprogramming the immune system to tolerate peanuts.  By creating a safe, convenient and fast solution to a very serious problem we believe our product will have a global health impact by transforming the lives of patients and their carers.

The vaccine is intended to be administered once per month via intra-dermal injection.

The objective of the Phase I study is two fold: (1) to determine the maximum dose that can be safely administered in a single injection, and (2) to assess the safety of repeat, escalating doses, administered once every 2 weeks.

Print or share this article

Click to visit sponsor
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of SnackSafely.com.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.